BACKGROUND: Considering limited therapeutic options and lack of consensus following cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) progression, we evaluated efficacy and safety of available treatments for hormone receptor-positive (HR+)/HER2- advanced breast cancer patients who progressed after CDK4/6i therapy. This evidence concerns the gene NR4A1 and breast carcinoma.